We discuss various strategies for treatment pauses in management of neovascular AMD, differences between bevacizumab and aflibercept in patients who can be successfully paused, and intra ocular biomarkers that may identify eyes in which treatment may be successful paused with Dr. Akrit Sodhi, Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine, Wilmer Eye Institute.